The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ZURA | +26.25% | N/A | N/A | -61% |
| S&P | +13.14% | +87.24% | +13.37% | +50% |
Zura Bio Ltd. is a clinical-stage biotechnology company that engages in the development of novel medicines for immune disorders. It focuses on the development of ZB-168, a treatment for Alopecia Areata and other inflammatory diseases. The company is headquartered in La Jolla, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.01M | -366.7% |
| Market Cap | $281.53M | 8.7% |
| Market Cap / Employee | $9.38M | 0.0% |
| Employees | 30 | 100.0% |
| Net Income | -$18.04M | 12.9% |
| EBITDA | -$19.51M | -1.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $139.02M | -26.1% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -37.55% | -7.0% |
| Return On Invested Capital | 1.36% | -10.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$15.48M | -173.1% |
| Operating Free Cash Flow | -$15.44M | -173.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.07 | 0.57 | 0.52 | 2.13 | 29.21% |
| Price to Tangible Book Value | 1.07 | 0.57 | 0.52 | 2.13 | 29.21% |
| Enterprise Value to EBITDA | 0.00 | 1.95 | 2.34 | -14.39 | 50.93% |
| Return on Equity | -44.0% | -62.3% | -46.3% | -47.9% | 15.48% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
